Production (Stage)
ArriVent BioPharma, Inc.
AVBP
$20.40
-$0.23-1.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.27M | 952.00K | 866.00K | 765.00K | 625.00K |
| Change in Net Operating Assets | -5.89M | 3.53M | 3.35M | 2.02M | -1.84M |
| Cash from Operations | -68.01M | -16.15M | -16.35M | -19.09M | -18.63M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 36.82M | -192.47M | -- | -- | -- |
| Cash from Investing | 36.82M | -192.47M | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.81M | 55.00K | 531.00K | 363.00K | 185.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00K | -- | -- | -- | -- |
| Cash from Financing | 6.76M | 55.00K | 531.00K | 363.00K | 185.63M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.43M | -208.56M | -15.81M | -18.72M | 167.00M |